Donnerstag 04. Mai 2017

TRAIN Akademie - Key Note Lecture

Öffentliche Vorlesung im Rahmen des Weiterbildungsprogramms „Translationale Forschung & Medizin: Von der Idee zum Produkt“ der TRAIN-Akademie:

Sprecher: Dr. Engin Gürlevik, Manager für Medizin und Wissenschaft | MSD SHARP& DOHME GmbH

"Innovative checkpoint inhibitors in cancer therapy: new career options in the pharmaceutical industry for academic employees"

Wann: Donnerstag, 04.05.2017, 16:30 Uhr

Wo: TWINCORE | Seminarraum 003

Vita

Engin Gürlevik studied biochemistry at Gottfried Wilhelm Leibniz Universität of Hannover from 1999 to 2005. Afterwards, he started his PhD thesis at Hannover Medical School on tumor-selective oncolytic adenoviruses. From 2009 to 2015, he continued his career as researcher and principal investigator at Hannover Medical School to establish new models for liver and pancreatic cancers, and to evaluate immunotherapeutic approaches in adjuvant and neoadjuvant settings. In 2015, he joined to MSD Sharp & Dohme as Medical Science Liaison to develop and represent the medical affairs immuno-oncology organization to the medical/scientific community.

Abstract

In recent years the increase of clinical trials and translational research have rapidly improved medical progress and offer thereby a great variety of jobs in the pharmaceutical industry for medical and scientific talents.
Cross-functional teams work closely to achieve market approval in very limited time. In this keynote lecture, job specifications and characterization of different departments like Medical Affairs, Regulatory Affairs, Pharmacovigilance, Clinical Research, Marketing and Market Access will be presented. For illustrational purpose, Dr. Gürlevik will present a typical working week of a Medical Scientific Liaison Manager Oncology, specialized in checkpoint inhibitors used in modern cancer therapy. 
In summary, the lecture provides an overview of activities and career options in the pharmaceutical industry.

Dateien:
TRAIN_KL_Guerlevik.pdf340 K